SightfileU.S. market data from official filings

ANAPTYSBIO INC (ANAB)

Name: ANAPTYSBIO INC (ANAB) — Institutional ownership, SEC filings and insider activity
Creator: Sightfile
License: https://www.sec.gov/privacy#dissemination

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001370053 · EDGAR filings · Updated 2026-07-13

ANAPTYSBIO INC (ANAB) has reported institutional ownership of 97.0%, with 206 institutional managers holding positions valued at $1.55B per the latest 13F reporting period.

Institutional ownership

97.0%

Institutional managers

206

Reported 13F value

$1.55B

Insider activity

79 trans.

−$9.42M net selling

Latest updates

2026-07-13 — Notice of proposed sale filed (Form 144)
2026-06-30 — Notice of proposed sale filed (Form 144)
2026-06-29 — Notice of proposed sale filed (Form 144)
2026-06-29 — ARS filed
2026-06-29 — DEFA14A filed
2026-06-29 — Proxy statement (DEF 14A) filed

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, ANAPTYSBIO INC has 206 institutional holders and institutional ownership of 97.0%.

Insider activity

Insiders reported 79 transactions (0 buys, 45 sells) across 11 reporting insiders, with a net reported value of −$9.42M.

Related companies

IMMUNOCORE HLDGS PLC (IMCR) · MBX BIOSCIENCES INC (MBX) · HARMONY BIOSCIENCES HLDGS IN (HRMY) · MAZE THERAPEUTICS INC (MAZE) · ENOVIS CORPORATION COM (ENOV) · ESTABLISHMENT LABS HLDGS INC (ESTA)

See full history, cross-references and alerts on Sightfile

Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-13.